FDA approves Actelion sNDA for second generation Veletri for injection
Veletri (epoprostenol) for injection is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. Actelion Pharmaceuticals president Shal Jacobovitz said, "Second
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.